A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Hydralazine (Hydralazine)

INDICATIONS AND USAGE Essential hypertension, alone or as an adjunct.

First FDA approval1990-09-30
Generic availableYes · 17 mfrs
Shortage statusActive shortage
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$119.9M in CY2024 Part D spend9.1M claims · 2.7M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.027/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.028
Across all dosage forms in distribution.
Highest NADAC
$0.036
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema10 entries indexed · 4 visible
What is Hydralazine used for?

INDICATIONS AND USAGE Essential hypertension, alone or as an adjunct.

Is there a generic for Hydralazine?

Yes. 42 ANDAs filed at FDA, 17 generic manufacturers currently shipping.

How much does my plan pay for Hydralazine?

Across 329 Part D plans, Hydralazine averages $0.028/unit (NADAC). Lowest available: $0.027/unit. Highest in distribution: $0.036/unit.

Is Hydralazine on the FDA shortage list?

Yes. Hydralazine is currently listed as an active FDA shortage.

6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Arteriolar Vasodilator1 alternative in D1
01
Minoxidil
Arteriolar Vasodilator
$0.095Lowest NADAC
3Generic mfrs
$14.7MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.